Navigation Links
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Date:9/28/2008

Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.

Metabolism refers to all the reactions by which living things break down nutrients to produce energy, along with those by which they rebuild broken-down nutrients into complex molecules (e.g. DNA). A significant example is the breakdown of blood sugar (e.g. glucose) and its conversation via chain reactions into adenosine triphosphate, the energy-storing currency of cellular life. As an important offshoot of that process, glucose can also be converted into fatty acids, the lipid building blocks of human hormones and cell membranes. Many viruses, including influenza, HIV and hepatitis, use those same fatty acids to build instead their viral envelopes, outer coatings that help them penetrate human cells. Going into the study, little was known about the mechanisms through which viruses hijack metabolic building blocks from their cellular hosts, with older techniques providing a limited picture.

In the current study, a team of researchers from the University of Rochester Medical Center and Princeton University created a new technique to clarify these mechanisms, and found that the technique could identify anti-viral therapeutic targets. Researchers combined drug discovery technologies to capture for the first time the exact concentrations and turnover, in other words, the fluxes, of interchangeable molecules within the metabolic chain reactions that convert sugars into fatty acids. The fields of metabolomics and fluxomics have emerged to measure these patterns, and to provide insight into diseases with a metabolic component, from diabetes to infectious diseases to cancer.

"Using new fluxomic techniques, our study reveals that viral infection takes control of cellular metabolism and drives
'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Consumers, Nurses, Seniors Tell Governor: Dont Break Your Promise to Protect Innocent Patients from Health Insurance Cancellations, Dont Weaken Existing Law
2. Small Businesses and the Self-Employed Need Stronger Coverage Protections for Pre-Existing Conditions
3. LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors
4. Drugs like aspirin could reduce breast cancer and help existing sufferers
5. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
6. MapMyRun.com Partners with End Result, Inc. to Offer Integrated Event Registration, Online Race Results with Their Existing Suite of Online Fitness Tools
7. Health Capital Group Warns of Fallout to Hospitals From the Subprime Mortgage Crisis and Urges Hospitals to Immediately Reassess Existing Debt Structures and Capital Financing Plans
8. Prostate Cancer Treatments Often Compound Existing Health Problems
9. The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off States Existing Six-Year Surcharge Period
10. Diabetes dilemma: older people with diabetes face a heavy burden from co-existing health conditions
11. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:CVS Caremark Names New Chief Human Resources Officer 2Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4National Alliance of Wound Care 28R 29 Launches On line Job Resource Center and New Website 60494 1National Alliance of Wound Care 28R 29 Launches On line Job Resource Center and New Website 60494 2ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement 5898 1ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement 5898 2ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement 5898 3ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement 5898 4Martel Instruments Expands Its Custom Printer Solutions Business in North America 3B Liz Peirce Named Director of North American Business Development 60491 1Martel Instruments Expands Its Custom Printer Solutions Business in North America 3B Liz Peirce Named Director of North American Business Development 60491 2